Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

Name: Aging 57 74

External Ids:

OMIM® 57 502000

Summaries for Aging

OMIM® : 57 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000) (Updated 05-Mar-2021)

MalaCards based summary : Aging is related to premature aging and werner syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vigabatrin and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Senescence (/sɪˈnɛsəns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1667)
# Related Disease Score Top Affiliating Genes
1 premature aging 32.5 WRN SOD2 PDGFRB LMNA
2 werner syndrome 32.4 WRN PARP1 LMNA
3 hutchinson-gilford progeria syndrome 32.1 WRN SOD2 SIRT6 SIRT1 LMNA
4 progeroid syndrome 31.6 WRN LMNA
5 age-related hearing loss 31.2 SOD2 SIRT1 HIF1A
6 huntington disease 30.8 SOD2 SIRT1 REST PPARG FOXO3
7 hyperglycemia 30.8 SOD2 PPARG NAMPT HIF1A
8 non-alcoholic fatty liver disease 30.7 SOD2 SIRT3 SIRT1 PPARG NAMPT
9 osteoporosis 30.7 WRN SOD2 SIRT6 SIRT1 PPARG LMNA
10 disease of mental health 30.6 SOD2 SIRT6 SIRT3 SIRT1 REST PPARG
11 optic atrophy 1 30.4 SOD2 SIRT3 SIRT1
12 type 2 diabetes mellitus 30.2 WRN SOD2 SIRT6 SIRT1 PPARG PARP1
13 body mass index quantitative trait locus 11 30.2 SOD2 SIRT6 SIRT3 SIRT1 PPARG NAMPT
14 non-alcoholic steatohepatitis 30.2 SOD2 SIRT1 PPARG
15 diabetes mellitus 29.9 WRN SOD2 SIRT3 SIRT1 PPARG PARP1
16 pellagra 29.8 PPARG PARP1 NAMPT
17 tuberous sclerosis 1 29.6 HIF1A FOXO3 FOXO1
18 burkitt lymphoma 29.1 SIRT1 PARP1 NFKB1 FOXO1
19 medulloblastoma 29.0 WRN SIRT1 REST PDGFRB PARP1 HIF1A
20 prostate cancer 28.8 TP63 SOD2 SIRT1 PPARG PDGFRB PARP1
21 premature aging syndrome, penttinen type 11.5
22 mild cognitive impairment 11.3
23 dementia 11.3
24 alzheimer disease 11.2
25 fontaine progeroid syndrome 11.2
26 branchiooculofacial syndrome 11.2
27 short stature, hearing loss, retinitis pigmentosa, and distinctive facies 11.2
28 premature aging syndrome, okamoto type 11.2
29 cockayne syndrome 11.1
30 impotence 11.0
31 gapo syndrome 11.0
32 presbyopia 11.0
33 refractive error 11.0
34 wiedemann-rautenstrauch syndrome 10.9
35 acrogeria, gottron type 10.9
36 nestor-guillermo progeria syndrome 10.9
37 sleep disorder 10.9
38 cerebroretinal microangiopathy with calcifications and cysts 2 10.9
39 ogden syndrome 10.9
40 laminopathy with premature aging 10.9
41 cerebral amyloid angiopathy, cst3-related 10.9
42 rickets 10.9
43 ataxia-telangiectasia 10.9
44 intraocular pressure quantitative trait locus 10.9
45 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.9
46 arthritis 10.9
47 senile cataract 10.9
48 trichothiodystrophy 10.9
49 rothmund-thomson syndrome, type 2 10.8
50 longevity 1 10.8

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging

Symptoms & Phenotypes for Aging

Clinical features from OMIM®:

502000 (Updated 05-Mar-2021)

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.1 NAMPT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.1 NAMPT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.1 NAMPT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.1 NAMPT SIRT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.1 NAMPT
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.1 NAMPT SIRT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.1 FOXO3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.1 NAMPT
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.1 NAMPT
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.1 HIF1A
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.1 NAMPT
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.1 NAMPT
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.1 NAMPT
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.1 PPARG
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.1 HIF1A
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.1 NAMPT
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.1 NAMPT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-208 10.1 FOXO3
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 10.1 FOXO3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.1 NAMPT
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 10.1 NAMPT
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.1 NAMPT
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 10.1 NAMPT
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.1 HIF1A
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 10.1 SIRT3
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.1 SIRT3
27 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 HIF1A NFKB1 SIRT1
28 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 FOXO3 HIF1A NFKB1
29 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 HIF1A NFKB1 PARP1 TP63 WRN

MGI Mouse Phenotypes related to Aging:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.57 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
2 cardiovascular system MP:0005385 10.52 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
3 growth/size/body region MP:0005378 10.51 FOXO1 GDF11 HIF1A LMNA NAMPT NFKB1
4 behavior/neurological MP:0005386 10.5 FOXO1 FOXO3 HIF1A LMNA NFKB1 PARP1
5 homeostasis/metabolism MP:0005376 10.48 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
6 immune system MP:0005387 10.44 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
7 integument MP:0010771 10.43 FOXO1 FOXO3 HIF1A LMNA NAMPT NFKB1
8 mortality/aging MP:0010768 10.43 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
9 hematopoietic system MP:0005397 10.4 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
10 adipose tissue MP:0005375 10.37 FOXO1 FOXO3 LMNA PDGFRB PPARG RGN
11 endocrine/exocrine gland MP:0005379 10.36 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
12 digestive/alimentary MP:0005381 10.34 FOXO1 FOXO3 GDF11 HIF1A LMNA NFKB1
13 craniofacial MP:0005382 10.3 FOXO1 GDF11 HIF1A LMNA NFKB1 PDGFRB
14 embryo MP:0005380 10.29 FOXO1 GDF11 HIF1A NAMPT PARP1 PDGFRB
15 nervous system MP:0003631 10.25 FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
16 liver/biliary system MP:0005370 10.19 FOXO1 HIF1A LMNA NFKB1 PPARG RGN
17 hearing/vestibular/ear MP:0005377 10.17 FOXO3 LMNA NFKB1 PARP1 PPARG REST
18 limbs/digits/tail MP:0005371 10.16 FOXO1 GDF11 HIF1A LMNA PDGFRB RGN
19 muscle MP:0005369 10.11 FOXO1 GDF11 HIF1A LMNA NFKB1 PDGFRB
20 neoplasm MP:0002006 10.03 FOXO1 FOXO3 HIF1A PPARG SIRT1 SOD2
21 reproductive system MP:0005389 10.03 FOXO1 FOXO3 LMNA PARP1 PDGFRB PPARG
22 normal MP:0002873 10.02 FOXO1 HIF1A LMNA NFKB1 PDGFRB PPARG
23 renal/urinary system MP:0005367 10.02 FOXO3 GDF11 HIF1A LMNA PARP1 PDGFRB
24 skeleton MP:0005390 9.8 FOXO1 FOXO3 GDF11 HIF1A LMNA NFKB1
25 respiratory system MP:0005388 9.76 FOXO3 GDF11 HIF1A LMNA NFKB1 RGN
26 vision/eye MP:0005391 9.5 FOXO3 GDF11 HIF1A LMNA NAMPT PARP1

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1483)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
2
Topiramate Approved Phase 4 97240-79-4 5284627
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
5
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
6
Desogestrel Approved Phase 4 54024-22-5 40973
7
Lactulose Approved Phase 4 4618-18-2 11333
8
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
9
Verteporfin Approved, Investigational Phase 4 129497-78-5
10
Abciximab Approved Phase 4 143653-53-6
11
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
12
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
13
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
14
Rufinamide Approved Phase 4 106308-44-5 129228
15
Stiripentol Approved Phase 4 49763-96-4
16
Nitrazepam Approved Phase 4 146-22-5 4506
17
Ethosuximide Approved Phase 4 77-67-8 3291
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
20
Lorazepam Approved Phase 4 846-49-1 3958
21
Nitric Oxide Approved Phase 4 10102-43-9 145068
22
Sulfamethoxazole Approved Phase 4 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
24
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
25
Metronidazole Approved Phase 4 443-48-1 4173
26
Ondansetron Approved Phase 4 99614-02-5 4595
27
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
28
Clarithromycin Approved Phase 4 81103-11-9 84029
29
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
30
Ethambutol Approved Phase 4 74-55-5 3279 14052
31
Morphine Approved, Investigational Phase 4 57-27-2 5288826
32
Fospropofol Approved, Illicit, Investigational Phase 4 258516-89-1, 258516-87-9 3038498
33
Levetiracetam Approved Phase 4 102767-28-2 441341
34
Pentetic acid Approved Phase 4 67-43-6
35
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
36
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
37
Budesonide Approved Phase 4 51333-22-3 63006 5281004
38
Nevirapine Approved Phase 4 129618-40-2 4463
39
Citalopram Approved Phase 4 59729-33-8 2771
40
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
41
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
42
Phenol Approved, Experimental Phase 4 108-95-2 996
43
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
44
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
45
carbamide peroxide Approved Phase 4 124-43-6
46
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
48
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
49
Insulin aspart Approved Phase 4 116094-23-6 16132418
50
Retapamulin Approved Phase 4 224452-66-8 6918462

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly Unknown status NCT00966199 Phase 4 anti-hypertensive medication
2 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
3 Comparing Effectiveness of Post-operative Analgesia Between Patient Re-education and the Additional of a Basal Morphine Infusion to IV-PCA Morphine in Patients With Unsatisfactory Analgesia After Laparotomy Unknown status NCT02523846 Phase 4 morphine
4 Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation Unknown status NCT01321047 Phase 4 Propofol;BPS
5 Inhaled Salbutamol in Elective Caesarean Section Unknown status NCT01978418 Phase 4 salbutamol;Placebo
6 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
7 Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension Unknown status NCT01427686 Phase 4 Dobutamine;Dopamine
8 The Effect of a Circuit Resistance Training, Empagliflozin or "Vegeterranean Diet" on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial) Unknown status NCT03560375 Phase 4 Empagliflozin 10 MG
9 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
10 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
11 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Unknown status NCT02123056 Phase 4 Metoprolol;Matching Placebo
12 A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging Unknown status NCT03465202 Phase 4 Capecitabine
13 Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users Unknown status NCT02945293 Phase 4
14 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
15 AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study Unknown status NCT03005236 Phase 4 ENVARSUS;Standard twice daily tacrolimus
16 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
17 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
18 Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF) Unknown status NCT01943396 Phase 4
19 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
20 A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD). Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
21 Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose Unknown status NCT02864472 Phase 4 Ranibizumab;ranibizumab PRN
22 Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD Unknown status NCT02810808 Phase 4 Ranibizumab
23 Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept Unknown status NCT03468296 Phase 4 Intravitreal Aflibercept Injection 2mg
24 Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) Unknown status NCT01961414 Phase 4 Aflibercept
25 Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Unknown status NCT01657669 Phase 4 Intravitreal Aflibercept injection
26 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
27 Early Cognitive Function and Recovery in Elderly Patients After Laser Laryngeal Surgery: Desflurane-based vs Propofol-based Anesthesia Unknown status NCT03194074 Phase 4 Propofol;Desflurane
28 Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial Unknown status NCT03346226 Phase 4 Dexmedetomidine Hydrochloride;Propofol
29 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
30 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
31 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
32 Oxidative Stress In Semen And Male Infertility Unknown status NCT03464656 Phase 4 Fairhaven Pro for men
33 Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
34 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
35 A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy Unknown status NCT03428724 Phase 4 Standard Preparation;Individualized Preparation
36 Influence of Albumin on the Development of Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation Unknown status NCT03373318 Phase 4 Human albumin;Plasmalyte
37 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
38 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
39 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
40 Randomized Control Trial of Dichloroacetate, Preoperative Carbohydrate Loading and Moderate Intensity Exercise on Muscle Insulin Resistance After Major Abdominal Surgery Unknown status NCT02469337 Phase 4 Dichloroacetate
41 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
42 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
43 The Acute Effects of Moderate Intensity Exercise and Caffeine Ingestion on Cognition in Non-Caffeine Consumers and Caffeine Consumers Unknown status NCT03400423 Phase 4 Caffeine
44 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
45 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Unknown status NCT01315015 Phase 4
46 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
47 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
48 A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT02677519 Phase 4 Aptensio XR
49 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
50 Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations Unknown status NCT01213667 Phase 4 Ranibizumab

Search NIH Clinical Center for Aging

Genetic Tests for Aging

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

40
Brain, Skin, Bone, Eye, Myeloid, Endothelial, Heart

Publications for Aging

Articles related to Aging:

(show top 50) (show all 30018)
# Title Authors PMID Year
1
Short telomeres are sufficient to cause the degenerative defects associated with aging. 57
19944403 2009
2
Increased cell-to-cell variation in gene expression in ageing mouse heart. 57
16791200 2006
3
Lamin A-dependent nuclear defects in human aging. 57
16645051 2006
4
Gene regulation and DNA damage in the ageing human brain. 57
15190254 2004
5
Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. 57
12538859 2003
6
Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. 57
12483296 2003
7
Genome dynamics in aging mice. 57
12421760 2002
8
Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. 57
11274426 2001
9
Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. 57
10900004 2000
10
Role of nuclear background and in vivo environment in variable segregation behavior of the aging-dependent T414G mutation at critical control site for human fibroblast mtDNA replication. 57
15328912 1999
11
Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. 57
10531063 1999
12
Mitochondrial genotype associated with longevity. 57
9449878 1998
13
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 57
1303288 1992
14
Growing old: the most common mitochondrial disease of all? 57
1303273 1992
15
Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. 57
1303287 1992
16
Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. 57
1463763 1992
17
Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. 57
1383763 1992
18
Mitochondrial genetics: a paradigm for aging and degenerative diseases? 57
1533953 1992
19
Icariin improves brain function decline in aging rats by enhancing neuronal autophagy through the AMPK/mTOR/ULK1 pathway. 61
33556283 2021
20
Astaxanthin alleviates pathological brain aging through the upregulation of hippocampal synaptic proteins. 61
33269751 2021
21
Preventive electroacupuncture reduces cognitive deficits in a rat model of D-galactose-induced aging. 61
33229729 2021
22
Blood pressure as a predictor of everyday cognitive function in aging adults with and without fibromyalgia. 61
32339069 2021
23
Volatile compounds sorption during the aging of Chinese Liquor (Baijiu) using Pottery Powder. 61
33310558 2021
24
Corrigendum to "The correlation of IRE1α oxidation with Nox4 activation in aging-associated vascular dysfunction" [Redox Biology 37 (2020) 101727]. 61
33579668 2021
25
Effect of Jiajian Guishen Formula on the senescence-associated heterochromatic foci in mouse ovaria after induction of premature ovarian aging by the endocrine-disrupting agent 4-vinylcyclohexene diepoxide. 61
33358858 2021
26
In-vivo diffusion MRI protocol optimization for the chimpanzee brain and examination of aging effects on the primate optic nerve at 3T. 61
33359631 2021
27
Gratitude as a Mediator of the Effects of Savoring on Positive Adjustment to Aging. 61
32370635 2021
28
Validation of a mass spectrometry method to identify and quantify ellagitannins in oak wood and cognac during aging in oak barrels. 61
33069531 2021
29
Effect of air-abrasion at pre- and/or post-sintered stage and hydrothermal aging on surface roughness, phase transformation, and flexural strength of multilayered monolithic zirconia. 61
33236475 2021
30
Seasonal variation of dicarboxylic acids in PM2.5 in Beijing: Implications for the formation and aging processes of secondary organic aerosols. 61
33131838 2021
31
Analysis of aging type- and aging time-related changes in the polar fraction of metabolome of beef by 1H NMR spectroscopy. 61
33092915 2021
32
Oxygen consumption rate of lees during sparkling wine (Cava) aging; influence of the aging time. 61
33051100 2021
33
Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. 61
33025390 2021
34
Effects of a 12-Week Cycling Intervention on Successful Aging Measures in Mid-Aged Adults. 61
32097099 2021
35
Biological aspects of aging that influence response to anticancer treatments. 61
33399393 2021
36
Aerobic exercise training decreases cognitive impairment caused by demyelination by regulating ROCK signaling pathway in aging mice. 61
33358939 2021
37
Interactions of iron-based nanoparticles with soil dissolved organic matter: adsorption, aging, and effects on hexavalent chromium removal. 61
33307452 2021
38
Risk- and protective factors for memory plasticity in aging. 61
32098566 2021
39
Probing menstrual bloodstain aging with fluorescence spectroscopy. 61
33279406 2021
40
Reservoir optimized plunger lift technology reduces hydrocarbon emissions from aging gas wells. 61
33208255 2021
41
Proteodynamics and aging of eukaryotic cells. 61
33421431 2021
42
Diabetes multimorbidity combinations and disability in the Mexican Health and Aging Study, 2012-2015. 61
33186887 2021
43
Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. 61
33386471 2021
44
Testing a Model of Successful Aging on Masters Athletes and Non-Sporting Adults. 61
32027570 2021
45
Human anterior pituitary's ACTH cells during the aging process: immunohistochemic and morphometric study. 61
33098535 2021
46
Editorial for "Cardiac MRI Reveals Late Diastolic Changes in Left Ventricular Relaxation Patterns During Healthy Aging". 61
33219621 2021
47
Critical Speed throughout Aging: Insight into the World Masters Championships. 61
33560767 2021
48
Integration of lncRNA and mRNA profiles to reveal the protective effects of Codonopsis pilosula extract on the gastrointestinal tract of mice subjected to D‑galactose‑induced aging. 61
33448313 2021
49
Accelerated aging: A marker for social factors resulting in cardiovascular events? 61
33532540 2021
50
Effect of enological treatments on phenolic and sensory characteristics of red wine during aging: Micro-oxygenation, sulfur dioxide, iron with copper and gelatin fining. 61
32871302 2021

Variations for Aging

Expression for Aging

Search GEO for disease gene expression data for Aging.

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 PPARG PDGFRB NFKB1 FOXO3 FOXO1
2 12.72 PPARG PDGFRB NFKB1 HIF1A FOXO1
3
Show member pathways
12.56 SIRT6 SIRT3 SIRT1 PDGFRB NFKB1
4
Show member pathways
12.51 PDGFRB NFKB1 HIF1A FOXO3 FOXO1
5 12.41 TP63 SIRT1 PDGFRB NFKB1
6 12.38 SOD2 SIRT3 SIRT1 PPARG NAMPT
7
Show member pathways
12.37 SIRT1 PPARG FOXO3 FOXO1
8
Show member pathways
12.15 SIRT6 SIRT3 SIRT1 HIF1A
9
Show member pathways
12.08 SIRT6 SIRT3 SIRT1 PARP1 NAMPT
10 12.03 SIRT1 NFKB1 FOXO3 FOXO1
11
Show member pathways
11.96 SOD2 SIRT1 FOXO3 FOXO1
12 11.89 PPARG NAMPT LMNA HIF1A FOXO1
13 11.86 SOD2 NFKB1 FOXO3
14 11.86 HIF1A FOXO3 FOXO1
15 11.76 PPARG NFKB1 FOXO3 FOXO1
16 11.67 SIRT1 FOXO3 FOXO1
17
Show member pathways
11.61 SOD2 SIRT1 PPARG NFKB1 FOXO3 FOXO1
18 11.6 SIRT6 SIRT3 PDGFRB HIF1A
19 11.58 NFKB1 HIF1A FOXO1
20
Show member pathways
11.39 SOD2 LMNA FOXO3
21 11.39 SOD2 SIRT1 FOXO3 FOXO1
22 11.37 SIRT6 SIRT3 SIRT1 PPARG NFKB1
23 11.25 SIRT1 NFKB1 FOXO1
24 11.21 SIRT3 SIRT1 FOXO3 FOXO1
25 10.94 WRN SIRT6 SIRT3 SIRT1
26 10.32 SIRT3 SIRT1 PPARG PARP1 NFKB1 NAMPT

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.13 WRN TP63 SOD2 SIRT6 SIRT1 RGN
2 mitochondrion GO:0005739 9.92 TP63 SOD2 SIRT3 SIRT1 PARP1 NFKB1
3 chromatin GO:0000785 9.91 TP63 SIRT1 PPARG NFKB1 HIF1A FOXO3
4 nucleus GO:0005634 9.86 WRN TP63 SIRT6 SIRT3 SIRT1 RGN
5 protein-containing complex GO:0032991 9.7 TP63 SIRT3 SIRT1 PARP1 HIF1A GDF11
6 nucleoplasm GO:0005654 9.47 WRN TP63 SIRT6 SIRT3 SIRT1 REST

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.22 TP63 SOD2 REST PPARG NFKB1 HIF1A
2 regulation of transcription, DNA-templated GO:0006355 10.21 TP63 REST PPARG NFKB1 HIF1A FOXO3
3 cellular response to DNA damage stimulus GO:0006974 10.04 WRN TP63 SIRT1 PARP1 FOXO1
4 apoptotic process GO:0006915 10.04 TP63 SIRT1 PARP1 NFKB1 FOXO3 FOXO1
5 negative regulation of cell proliferation GO:0008285 10.03 SOD2 REST PPARG LMNA GDF11
6 negative regulation of transcription, DNA-templated GO:0045892 10.02 TP63 SIRT1 REST PPARG NFKB1 FOXO1
7 positive regulation of transcription, DNA-templated GO:0045893 9.98 TP63 REST PPARG NFKB1 HIF1A FOXO3
8 negative regulation of gene expression GO:0010629 9.97 SIRT1 REST NFKB1 HIF1A
9 negative regulation of transcription by RNA polymerase II GO:0000122 9.91 TP63 SIRT6 SIRT1 REST PPARG PARP1
10 positive regulation of apoptotic process GO:0043065 9.88 SIRT1 REST PPARG PDGFRB FOXO3 FOXO1
11 negative regulation of apoptotic process GO:0043066 9.87 SOD2 SIRT1 RGN PDGFRB NFKB1 HIF1A
12 cellular response to insulin stimulus GO:0032869 9.83 PPARG PARP1 FOXO1
13 cellular response to starvation GO:0009267 9.81 WRN SIRT1 FOXO1
14 cellular response to oxidative stress GO:0034599 9.78 SOD2 PARP1 FOXO3 FOXO1
15 positive regulation of autophagy GO:0010508 9.77 HIF1A FOXO3 FOXO1
16 response to hydrogen peroxide GO:0042542 9.75 SOD2 SIRT1 PDGFRB
17 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.71 PPARG HIF1A FOXO3
18 cell aging GO:0007569 9.7 WRN TP63 SIRT1
19 response to lipid GO:0033993 9.67 PPARG PDGFRB
20 multicellular organism aging GO:0010259 9.67 WRN TP63
21 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.65 SOD2 SIRT1
22 white fat cell differentiation GO:0050872 9.65 SIRT1 PPARG
23 DNA synthesis involved in DNA repair GO:0000731 9.65 WRN SIRT1
24 positive regulation of transcription by RNA polymerase II GO:0045944 9.65 TP63 SIRT1 REST PPARG PARP1 NFKB1
25 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.64 SOD2 PPARG
26 negative regulation of cellular senescence GO:2000773 9.63 TP63 SIRT1 NAMPT
27 negative regulation of cardiac muscle hypertrophy in response to stress GO:1903243 9.62 LMNA FOXO1
28 retina vasculature development in camera-type eye GO:0061298 9.61 PDGFRB HIF1A
29 peptidyl-lysine deacetylation GO:0034983 9.61 SIRT3 SIRT1
30 oxygen homeostasis GO:0032364 9.6 SOD2 HIF1A
31 cellular response to hyperoxia GO:0071455 9.58 PPARG FOXO1
32 positive regulation of superoxide dismutase activity GO:1901671 9.56 SIRT3 RGN
33 protein deacetylation GO:0006476 9.54 SIRT6 SIRT3 SIRT1
34 histone H3-K9 deacetylation GO:1990619 9.51 SIRT6 SIRT1
35 histone H3-K9 modification GO:0061647 9.49 SIRT6 SIRT1
36 protein ADP-ribosylation GO:0006471 9.46 SIRT6 SIRT3 SIRT1 PARP1
37 aging GO:0007568 9.17 WRN TP63 SOD2 SIRT3 RGN PDGFRB

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.22 WRN TP63 SOD2 REST PPARG PARP1
2 identical protein binding GO:0042802 10.14 TP63 SOD2 SIRT1 PPARG PARP1 NFKB1
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.11 TP63 REST PPARG NFKB1 HIF1A FOXO3
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 10.11 TP63 SIRT1 REST PPARG NFKB1 HIF1A
5 DNA-binding transcription factor activity GO:0003700 9.98 TP63 REST PPARG NFKB1 HIF1A FOXO3
6 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.96 TP63 NFKB1 HIF1A FOXO3 FOXO1
7 chromatin binding GO:0003682 9.93 WRN TP63 REST PPARG NFKB1 FOXO1
8 DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001227 9.89 REST PPARG NFKB1 FOXO3
9 transcription regulatory region sequence-specific DNA binding GO:0000976 9.88 TP63 REST PPARG NFKB1 FOXO3
10 transcription factor binding GO:0008134 9.85 SIRT1 REST PPARG PARP1 NFKB1 HIF1A
11 enzyme binding GO:0019899 9.8 SOD2 SIRT3 SIRT1 PPARG PDGFRB PARP1
12 p53 binding GO:0002039 9.72 TP63 SIRT1 HIF1A
13 deacetylase activity GO:0019213 9.58 SIRT6 SIRT1
14 protein deacetylase activity GO:0033558 9.58 SIRT6 SIRT1
15 NAD+ binding GO:0070403 9.58 SIRT6 SIRT3 SIRT1
16 NAD-dependent protein deacetylase activity GO:0034979 9.5 SIRT6 SIRT3 SIRT1
17 NAD-dependent histone deacetylase activity (H3-K9 specific) GO:0046969 9.49 SIRT6 SIRT1
18 NAD+ ADP-ribosyltransferase activity GO:0003950 9.46 SIRT6 SIRT3 SIRT1 PARP1
19 sequence-specific DNA binding GO:0043565 9.23 TP63 SIRT3 REST PPARG NFKB1 HIF1A
20 NAD-dependent histone deacetylase activity GO:0017136 9.13 SIRT6 SIRT3 SIRT1

Sources for Aging

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....